S&P 500   3,958.21 (-0.49%)
DOW   32,350.40 (-0.25%)
QQQ   305.76 (-0.97%)
AAPL   156.51 (-1.12%)
MSFT   273.31 (-1.11%)
META   199.56 (-1.62%)
GOOGL   100.83 (-1.59%)
AMZN   97.44 (-0.61%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.50 (+14.38%)
AMD   93.52 (-3.20%)
T   18.80 (-0.37%)
F   11.54 (+0.17%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   93.04 (-0.29%)
DIS   95.04 (-0.61%)
AMC   4.80 (+5.49%)
PFE   40.04 (-0.45%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,958.21 (-0.49%)
DOW   32,350.40 (-0.25%)
QQQ   305.76 (-0.97%)
AAPL   156.51 (-1.12%)
MSFT   273.31 (-1.11%)
META   199.56 (-1.62%)
GOOGL   100.83 (-1.59%)
AMZN   97.44 (-0.61%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.50 (+14.38%)
AMD   93.52 (-3.20%)
T   18.80 (-0.37%)
F   11.54 (+0.17%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   93.04 (-0.29%)
DIS   95.04 (-0.61%)
AMC   4.80 (+5.49%)
PFE   40.04 (-0.45%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,958.21 (-0.49%)
DOW   32,350.40 (-0.25%)
QQQ   305.76 (-0.97%)
AAPL   156.51 (-1.12%)
MSFT   273.31 (-1.11%)
META   199.56 (-1.62%)
GOOGL   100.83 (-1.59%)
AMZN   97.44 (-0.61%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.50 (+14.38%)
AMD   93.52 (-3.20%)
T   18.80 (-0.37%)
F   11.54 (+0.17%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   93.04 (-0.29%)
DIS   95.04 (-0.61%)
AMC   4.80 (+5.49%)
PFE   40.04 (-0.45%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,958.21 (-0.49%)
DOW   32,350.40 (-0.25%)
QQQ   305.76 (-0.97%)
AAPL   156.51 (-1.12%)
MSFT   273.31 (-1.11%)
META   199.56 (-1.62%)
GOOGL   100.83 (-1.59%)
AMZN   97.44 (-0.61%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.50 (+14.38%)
AMD   93.52 (-3.20%)
T   18.80 (-0.37%)
F   11.54 (+0.17%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   93.04 (-0.29%)
DIS   95.04 (-0.61%)
AMC   4.80 (+5.49%)
PFE   40.04 (-0.45%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
NASDAQ:MBIO

Mustang Bio - MBIO Stock Forecast, Price & News

$0.36
+0.00 (+0.28%)
(As of 03/28/2023 01:13 PM ET)
Add
Compare
Today's Range
$0.36
▼
$0.37
50-Day Range
$0.35
▼
$0.72
52-Week Range
$0.32
▼
$1.16
Volume
75,212 shs
Average Volume
428,210 shs
Market Capitalization
$38.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Mustang Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,238.0% Upside
$4.75 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Mustang Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.76) to ($0.82) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

355th out of 1,002 stocks

Pharmaceutical Preparations Industry

159th out of 488 stocks

See Top Rated MarketRank™ Stocks Here

MBIO stock logo

About Mustang Bio (NASDAQ:MBIO) Stock

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

MBIO Stock News Headlines

March 20, 2023 | americanbankingnews.com
Mustang Bio (MBIO) to Release Quarterly Earnings on Tuesday
February 17, 2023 | usatoday.com
Ford cuts price of Mustang Mach-E to compete with Tesla, offers deal to recent buyers too
March 28, 2023 | Investing Daily (Ad)
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
December 19, 2022 | finance.yahoo.com
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
November 15, 2022 | finanznachrichten.de
Mustang Bio, Inc.: Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
October 6, 2022 | baystreet.ca
Mustang Bio Unchanged on Test Results
October 6, 2022 | finance.yahoo.com
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
September 23, 2022 | seekingalpha.com
Mustang Bio: This Horse May Gallop Still
March 28, 2023 | Investing Daily (Ad)
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
September 8, 2022 | finance.yahoo.com
Mustang Bio to Participate in Upcoming September 2022 Investor Conferences
September 2, 2022 | finance.yahoo.com
Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing
August 19, 2022 | seekingalpha.com
Mustang Bio (MBIO) Corporate Presentation - Slideshow
August 12, 2022 | benzinga.com
Recap: Mustang Bio Q2 Earnings
July 23, 2022 | nasdaq.com
Mustang Bio, Inc. (NASDAQ:MBIO) Shares Could Be 50% Below Their Intrinsic Value Estimate
July 17, 2022 | finance.yahoo.com
Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their holding by 9.9% earlier this year
July 15, 2022 | uk.finance.yahoo.com
Mustang Bio, Inc. (MBIO)
June 22, 2022 | msn.com
Mustang Bio Shares Gain As FDA Grants Orphan Drug Status To Waldenstrom Drug
June 22, 2022 | seekingalpha.com
Mustang Bio CAR T cell therapy for rare blood cancer gets FDA orphan drug status
June 22, 2022 | marketwatch.com
Mustang Bio Gets Orphan Drug Designation for MB-106 Lymphoma Treatment
June 22, 2022 | finance.yahoo.com
Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia
June 13, 2022 | seekingalpha.com
Mustang Bio updates interim data for blood cancer candidate
June 13, 2022 | finance.yahoo.com
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
May 19, 2022 | seekingalpha.com
Mustang announces positive data from gene therapy trial to treat X-linked immunodeficiency
May 19, 2022 | finance.yahoo.com
Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency
May 12, 2022 | finance.yahoo.com
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 12, 2022 | finance.yahoo.com
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress
May 4, 2022 | seekingalpha.com
Mustang Bio: The Market Is Missing This Opportunity
See More Headlines
Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

MBIO Company Calendar

Last Earnings
11/12/2021
Today
3/28/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBIO
CUSIP
N/A
CIK
1680048
Web
www.mustangbio.com
Phone
(781) 652-4500
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,215.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-66,370,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-87.56%
Return on Assets
-63.25%

Debt

Debt-to-Equity Ratio
0.42
Current Ratio
6.97
Quick Ratio
6.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.19 per share
Price / Book
0.30

Miscellaneous

Outstanding Shares
107,300,000
Free Float
105,158,000
Market Cap
$38.75 million
Optionable
Optionable
Beta
1.91

Key Executives

  • Manuel LitchmanManuel Litchman
    President, Chief Executive Officer & Director
  • Eliot M. Lurier
    Chief Financial Officer
  • Albert Paszek
    Executive Director-Technology
  • Bruce Dezube
    Senior Vice President & Head-Clinical Development
  • Susan E. Ward
    Vice President-Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













MBIO Stock - Frequently Asked Questions

Should I buy or sell Mustang Bio stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBIO shares.
View MBIO analyst ratings or view top-rated stocks.

What is Mustang Bio's stock price forecast for 2023?

3 equities research analysts have issued twelve-month target prices for Mustang Bio's stock. Their MBIO share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 1,215.4% from the stock's current price.
View analysts price targets for MBIO or view top-rated stocks among Wall Street analysts.

How have MBIO shares performed in 2023?

Mustang Bio's stock was trading at $0.3949 at the beginning of 2023. Since then, MBIO shares have decreased by 8.6% and is now trading at $0.3611.
View the best growth stocks for 2023 here.

Are investors shorting Mustang Bio?

Mustang Bio saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 144,400 shares, a drop of 45.3% from the February 28th total of 264,000 shares. Based on an average daily trading volume, of 458,900 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the shares of the company are short sold.
View Mustang Bio's Short Interest.

When is Mustang Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our MBIO earnings forecast.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) issued its quarterly earnings results on Friday, November, 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.01.

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu BioPharma (AYTU) and Kadmon (KDMN).

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.40%), GSA Capital Partners LLP (0.38%), HighTower Advisors LLC (0.28%), Morgan Stanley (0.26%), Millennium Management LLC (0.23%) and Jane Street Group LLC (0.13%). Insiders that own company stock include Brian Achenbach, Lindsay A Md Rosenwald and Manuel Md Litchman.
View institutional ownership trends.

How do I buy shares of Mustang Bio?

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $0.36.

How much money does Mustang Bio make?

Mustang Bio (NASDAQ:MBIO) has a market capitalization of $38.75 million. The company earns $-66,370,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Mustang Bio have?

The company employs 102 workers across the globe.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The official website for the company is www.mustangbio.com. The company can be reached via phone at (781) 652-4500 or via email at ir@mustangbio.com.

This page (NASDAQ:MBIO) was last updated on 3/28/2023 by MarketBeat.com Staff